



# National Consensus Standards for Neurology, Spring 2019 Cycle

Standing Committee Measure Evaluation Web Meeting

*June 27, 2019*

# NQF Staff

- Project staff
  - ▣ *Debjani Mukherjee, Senior Director*
  - ▣ *Michael Abrams, Senior Director*
  - ▣ *Yetunde Ogungbemi, Project Manager*
  
- NQF Quality Measurement leadership staff
  - ▣ *Elisa Munthali, Senior Vice President*

# Today's Agenda

- Welcoming Remarks and Review of Meeting Objectives
- Introductions and Disclosures of Interest
- NQF Member and Public Comment
- Consideration of Candidate Measures
- NQF Member and Public Comment
- Review of Next Steps
- Adjourn

# Introductions and Disclosures of Interest

# Neurology Standing Committee

- David Knowlton, MA
- David Tirschwell, MD, MSc
- David Andrews
- Jocelyn Bautista, MD
- Ketan Bulsara, MD
- James Burke, MD
- Michelle Camicia, MSN, RN, PHN, CRRN, CCM, FAHA
- Valerie Cotter, DrNP, AGPCNP-BC, FAANP
- Bradford Dickerson, MD, MMSC
- Dorothy Edwards, PhD
- Reuven Ferziger, MD
- Charlotte Jones, MD, PhD, MSPH
- Michael Kaplitt, MD, PhD
- Melody Ryan, PharmD, MPH
- Jane Sullivan, PT, DHS, MS
- Kelly Sullivan, PhD
- Ross Zafonte, DO

# Portfolio Review

# Neurology Portfolio of Measures

- This project will evaluate measures related to neurological conditions that can be used for accountability and public reporting for all populations and in all settings of care.
- NQF solicits new measures for possible endorsement
- NQF currently has 18 endorsed measures within this topic area. Endorsed measures undergo periodic evaluation to maintain endorsement—“maintenance”.

# Neurology Portfolio of NQF-Endorsed Measures

## Stroke

0437 STK 04: Thrombolytic Therapy

0437e STK 04: Thrombolytic Therapy

0467 Acute Stroke Mortality Rate (IQI 17)

0507 Diagnostic Imaging Stenosis Measurement in Carotid Imaging Reports

0661 Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT or MRI Scan Interpretation within 45 minutes of ED Arrival

1952 Time to Intravenous Thrombolytic Therapy

2863 CSTK 06: Nimodipine Treatment Administered

2864 CSTK 01: National Institutes of Health Stroke Scale (NIHSS) Score Performed for Ischemic Stroke Patients

2866 CSTK 03: Severity Measurement Performed for Subarachnoid Hemorrhage and Intracerebral Hemorrhage Patients

2877e Hybrid, Hospital 30-day, all-cause, risk-standardized mortality rate (RSMR) following acute ischemic stroke with risk adjustment for stroke severity

## Dementia

2872e Dementia – Cognitive Assessment (approved for trial use)

2111 Antipsychotic Use in Persons with Dementia



# Neurology Portfolio of NQF-Endorsed Measures (Reserve Status)

## Stroke

0434 STK 01: Venous Thromboembolism (VTE) Prophylaxis

0435 STK 02: Discharged on Antithrombotic Therapy

0436 STK 03: Anticoagulation Therapy for Atrial Fibrillation/Flutter

0438 STK 05: Antithrombotic Therapy By End of Hospital Day Two

0439 STK 06: Discharged on Statin Medication

0441 STK 10: Assessed for Rehabilitation

# Overview of the Measure Evaluation Process

# Roles of the Standing Committee

## *During the Evaluation Meeting*

- Act as a proxy for the NQF multistakeholder membership
- Work with NQF staff to achieve the goals of the project
- Evaluate each measure against each criterion
  - ▣ *Indicate the extent to which each criterion is met and rationale for the rating*
- Make recommendations regarding endorsement to the NQF membership
- Oversee portfolio of Neurology measures

# Ground Rules for Today's Meeting

## **During the discussions, Committee members should:**

- Be prepared, having reviewed the measures beforehand
- Base evaluation and recommendations on the measure evaluation criteria and guidance
- Remain engaged in the discussion without distractions
- Keep comments concise and focused
- Avoid dominating a discussion and allow others to contribute
- Indicate agreement without repeating what has already been said

# Process for Measure Discussion and Voting

- Brief introduction by measure developer (2-3 minutes)
- Lead discussants will begin Committee discussion for each criterion:
  - ▣ *Briefly explaining information on the criterion provided by the developer*
  - ▣ *Providing a brief summary of the pre-meeting evaluation comments*
  - ▣ *Emphasizing areas of concern or differences of opinion*
  - ▣ *Noting, if needed, the preliminary rating by NQF*
    - » This rating is intended to be used as a guide to facilitate the Committee's discussion and evaluation.
- Developers will be available to respond to questions at the discretion of the Committee
- Full Committee will discuss, then vote on the criterion, if needed, before moving on to the next criterion

# Voting

- Votes will be taken after the discussion of each criterion
- Importance to measure and report (must pass):
  - ▣ *Vote on Evidence*
  - ▣ *Vote on Gap*
- Scientific acceptability of measure properties (must pass):
  - ▣ *Vote on Reliability*
  - ▣ *Vote on Validity*
- Feasibility
- Use (must pass)
  - ▣ *Must pass for maintenance measures*
- Usability
- **If a measure does not pass a must-pass criterion, discussion and subsequent voting on remaining criteria will stop.**
- **Vote on the measure as specified.**

# Achieving Consensus

- Quorum: 66% of the Committee
- Pass/Recommended: Greater than 60% “Yes” votes of the quorum (this percent is the sum of high and moderate)
- Consensus not reached (CNR): 40-60% “Yes” votes (inclusive of 40% and 60%) of the quorum
- Does not pass/Not Recommended: Less than 40% “Yes” votes of the quorum
- CNR measures move forward to public and NQF member comment and the Committee will revote

# Opportunity for Member and Public Comment



# Consideration of Candidate Measures

# Review of Measure 2872e

- **Title:** Dementia: Cognitive Assessment
- **Developer:** Physician Consortium for Performance Improvement
- **Measure Type:** Process
- **Data Source:** Electronic Health Records
- **Level of Analysis:** Clinician: Group/Practice
- **Care Setting:** Inpatient/Hospital, Outpatient Services, Other
- **Reviewed 1 time:**
  - ▣ *Original Endorsement Date: September 23, 2016*
  - ▣ *Most Recent Update: September 23, 2016*
- **Status:** Endorsed

# Opportunity for Member and Public Comment

# Activities and Timeline **Spring 2019** Review Cycle

\*All times ET

Activity	Date
Measure Submission Deadline	April 2, 2019
Commenting & member support period on submitted measures opens	Wednesday, April 24, 2019
<b>Measure Evaluation Web Meeting</b>	<b>Thursday, June 27, 2019, 1-3 pm ET</b>
Draft Report Posted for Public Comment	July 25-August 23, 2019
<b>Post Draft Report Comment Call</b>	<b>Wednesday, September 11, 2019, 1-3 pm ET</b>
CSAC Review Period	October 8-October 28, 2019
Appeals Period	October 30-November 28, 2019

# Project Contact Info

- Email: [Neurology@qualityforum.org](mailto:Neurology@qualityforum.org)
- NQF phone: 202-783-1300
- Project page:  
[http://www.qualityforum.org/Project\\_Pages/Neurology.aspx](http://www.qualityforum.org/Project_Pages/Neurology.aspx)
- SharePoint site:  
<http://share.qualityforum.org/Projects/Neurology%202015/SitePages/Home.aspx>

THANK YOU